Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Recruiting · NCT04985058 · Observational (researchers observe without assigning treatment) · Lead sponsor: Hellenic Cooperative Oncology Group
View the official record on ClinicalTrials.gov →What this trial is about
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed HR-positive, HER2-negative breast cancer
- Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
- 18 years or older
- Any menopausal status
- Treatment with abemaciclib in combination with endocrine therapy
- Any endocrine therapy
- At least two months of treatment with abemaciclib
Where it is running
1 location listed.
- Hellenic Oncology Cooperative Group - Athens, Greece